How to use PRISM

A finding-driven management assistant. Walk through a case the way you'd present it to a colleague, and get an evidence-linked treatment plan at the end.

Photograph of white light entering a glass prism and dispersing into a spectrum

PRISM Module 1 - Retina v5.52

Protocols, Recommendations & Interventions for Standardised Management

Diabetic Retinopathy —

Age & sex
Age
Sex
Diabetes profile
Diabetes type
Duration of diabetes
Concurrent disease
Select all that apply
Glycemic control
HbA1c control
Has HbA1c fallen sharply in the last few months?For example, after starting insulin or an insulin pump, a GLP-1 drug, or weight-loss surgery. A large, quick fall can temporarily worsen retinopathy, so the patient should be seen sooner. This is not a reason to slow down improving control.
Prior ocular treatment (this eye)
Select all that apply
Lens & steroid history (this eye)
Lens status (this eye)
Glaucoma / ocular hypertension history (this eye)
Prior intravitreal steroid trial (this eye)
Retinopathy grade
Severity (ICDR) required
Macular edema required
Follow-up & symmetry
Reliable follow-up likely?
Marked asymmetry in retinopathy severity between eyes
BCVA
BCVA — this eye
BCVA — fellow eye
Proliferative & neovascular features
Select all that apply
Anterior-segment neovascularization
Intraocular pressure (this eye)
OCT findings
OCT CST (µm)
Vitreomacular traction / ERM on OCT
DRIL on OCT
Macular ischemia (OCTA/FA)
B-scan ultrasound
Retinal status
PVD status
Vitreous hemorrhage density
Fundus view

Welcome to PRISM — Diabetic Retinopathy

A finding-driven management assistant. Walk through a case the way you'd present it to a colleague, and get an evidence-linked treatment plan at the end.

1

Start a new case

Tap "Start New Case" below. Each case covers one eye — the eye being treated. For the other eye, start a new case.

2

Work through the cards

Up to 12 short cards in three phases — History, Examination, Investigations — with a small phase label at the top of each. Cards that don't apply to the case are skipped. Single-choice cards move on by themselves; cards where you tick several findings, or that have an optional measurement such as OCT thickness, wait for you to tap Next, which glows when the card is complete. Use the arrows to go back, or the ✕ to exit.

3

Mismatches get caught as you go

If two answers don't add up — say, a finding that doesn't fit the current severity grade — a note appears right on that card explaining why. A small counter above the cards tracks how many are still outstanding at any time; tap either the note or the counter to jump straight to what needs a second look.

4

Get the plan

The plan opens with the Current Recommendation. It starts with a short summary — what this eye has and what to do — then lists what to investigate before deciding (if anything), what to treat now, and the follow-up interval, and ends with "Answers that decided this plan" — the answers that, if changed, would change the plan. Every line has a "Why this?" with the reasoning and the trial evidence. Below it are other options to consider and what isn't needed at this stage. "Edit case" takes you back to the cards with your answers kept, and "Print / Save PDF" gives a one- or two-page summary of the case and plan.

5

Check the evidence

Tap "Evidence Driven Management" under the title to see every trial PRISM uses (and one key observational study), by topic or by year — each with plain-language results and the number of patients enrolled.

Disclaimer. PRISM is a decision-support and teaching tool for ophthalmologists. It does not replace clinical examination, judgement or responsibility for patient care. Recommendations are based on the AAO Preferred Practice Pattern (2025), ADA Standards of Care (2026) and DRCR Retina Network trial evidence as of the version date, and may not cover every clinical situation, co-existing eye disease or newer evidence. Each case covers one eye. Advice on systemic medicines (glucose-lowering, lipid, pregnancy-related) should be confirmed with the patient's treating physician. Case details are used only to calculate the plan and are not stored. The author accepts no liability for decisions made using this tool.
▾ scroll for more

Management Plan

For review and confirmation by the treating ophthalmologist
Case summary
Sources (56)
  1. Lim JI, Kim SJ, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern. Ophthalmology. 2025;132(4):P75–P162.
  2. ADA. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S261–S276.
  3. DRCR Retina Network Protocol S. PRP vs Ranibizumab for PDR. JAMA. 2015;314(20):2137–2146; 5-year outcomes: Gross JG, et al. JAMA Ophthalmol. 2018.
  4. DRCR Retina Network Protocol I/T. Anti-VEGF for center-involving DME.
  5. Brown DM, Wykoff CC, Boyer D, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(9):946–955.
  6. Maturi RK, et al. DRCR Retina Network Protocol W: Effect of Intravitreous Anti-VEGF Therapy on Progression of Diabetic Retinopathy in Eyes With Moderately Severe to Severe NPDR. JAMA Ophthalmol. 2021;139(7):701–712 (4-year results: 2023).
  7. Baker CW, et al. DRCR Retina Network Protocol V: Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With DME and Good Visual Acuity. JAMA. 2019;321(19):1880–1894.
  8. Diabetic Retinopathy Vitrectomy Study (DRVS) Research Group. Arch Ophthalmol. 1985–1990 series.
  9. DCCT/EDIC Research Group. N Engl J Med. 1993 & follow-up.
  10. Keech AC, et al. FIELD Study Investigators. Fenofibrate and diabetic retinopathy. Lancet. 2007;370(9600):1687–1697; ACCORD Study Group/ACCORD Eye Study Group. N Engl J Med. 2010;363(3):233–244.
  11. Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Ophthalmol. 2021. doi:10.1001/jamaophthalmol.2021.0640
  12. Marso SP, et al. SUSTAIN-6: semaglutide and cardiovascular outcomes in type 2 diabetes (retinopathy complications signal). N Engl J Med. 2016;375(19):1834–1844.
  13. Diabetic Retinopathy Vitrectomy Study (DRVS) Research Group; subsequent NVG management literature on combined anti-VEGF/PRP/IOP-lowering therapy.
  14. Wells JA, et al. DRCR Retina Network Protocol T: Aflibercept, Bevacizumab, or Ranibizumab for DME. N Engl J Med. 2015;372(13):1193–1203 (2-year results: Ophthalmology. 2016).
  15. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19mg — FDA Prescribing Information: indicated only in patients previously treated with a corticosteroid course without a clinically significant IOP rise.
  16. Boyer DS, et al. Dexamethasone intravitreal implant in vitrectomized patients with DME. Retina. 2011;31(5):915–923.
  17. Antoszyk AN, et al. DRCR Retina Network Protocol AB: Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From PDR. JAMA. 2020;324(23):2383–2395.
  18. OZURDEX (dexamethasone intravitreal implant) — FDA Prescribing Information, revised 3/2026: contraindicated with a torn or ruptured posterior lens capsule and in glaucoma with cup-to-disc ratio >0.8; IOP rise in the DME trials.
  19. Obeid A, et al. Ophthalmology. 2019 — outcomes of eyes with PDR lost to follow-up after PRP vs intravitreal anti-VEGF.
  20. Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2023;4:CD007920.
  21. Arevalo JF, et al. Br J Ophthalmol. 2008;92(2):213 — tractional detachment after intravitreal bevacizumab in severe PDR.
  22. Myint KT, et al. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2022 (CD010790).
  23. DRCR Network Writing Committee, Haller JA, et al. (Protocol D). Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087–1093.
  24. Jhaveri CD, Glassman AR, Ferris FL 3rd, et al. (Protocol AC). Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med. 2022;387(8):692–703.
  25. Marcus DM, Silva PS, Liu D, et al. (Protocol AA). Association of predominantly peripheral lesions on ultra-widefield imaging and the risk of diabetic retinopathy worsening over time. JAMA Ophthalmol. 2022;140:946–954.
  26. American College of Obstetricians and Gynecologists, with the American Society of Anesthesiologists. Committee Opinion No. 775: Nonobstetric Surgery During Pregnancy. 2019.
  27. Thompson A, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. J Am Coll Cardiol. 2024;84(19):1869–1969.
  28. Anesthesia Patient Safety Foundation (APSF). Perioperative Stroke Prevention: A Review of Recent Guidelines for Noncardiac and Nonneurologic Surgery.
  29. OpenAnesthesia (International Anesthesia Research Society). Regional Anesthesia for Ophthalmic Surgery.
  30. Diabetic Retinopathy Clinical Research Network Writing Committee (Protocol Q). Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol. 2013;131(7):870–879.
  31. Wykoff CC. Thresholds for initiating treatment of eyes with diabetic macular edema and good vision: consideration of DRCR.Net Protocol V results. Ophthalmol Retina. 2019;3(11):917–919.
  32. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY). Lancet. 2017;389(10085):2193–2203.
  33. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (MEAD). Ophthalmology. 2014;121(10):1904–1914.
  34. Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123–137.
  35. Kim SJ, Schoenberger SD, Thorne JE, et al. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology (Ophthalmic Technology Assessment). Ophthalmology. 2015.
  36. Halvorsen S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826–3924.
  37. Jørgensen ME, et al. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. JAMA. 2014;312(3):269–277.
  38. Confalonieri F, Ferraro V, Di Maria A, et al. Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review. Life. 2023;13(6):1362.
  39. Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26.
  40. Urbonavičiūtė D, Buteikienė D, Janulevičienė I. A review of neovascular glaucoma: etiology, pathogenesis, diagnosis, and treatment. Medicina. 2022;58(12):1870.
  41. Mir T, Iftikhar M, Seidel N, et al. Clinical characteristics and outcomes of hyphema in patients with sickle cell disease or trait. Clin Ophthalmol. 2020;14:4165–4172.
  42. Wielders LHP, et al. ESCRS PREMED Study Report 2: prevention of cystoid macular edema after cataract surgery in diabetic patients. J Cataract Refract Surg. 2018;44(7):836–847.
  43. De Maria M, Panchal B, Coassin M. Update on indications for diabetic vitrectomy and management of complications. Ann Eye Sci. 2018;3:51.
  44. Hajee F, Makgotloe A. Surgical management of tractional retinal detachment in diabetic retinopathy. Afr Vision Eye Health. 2022;81(1).
  45. National Institute for Health and Care Excellence. Diabetic retinopathy: management and monitoring (NG242). 2024.
  46. Sun JK, et al. Rationale and application of the Protocol S anti-VEGF algorithm for proliferative diabetic retinopathy. Ophthalmology. 2019;126:87–95.
  47. Hoguet A, et al. The effect of anti-VEGF agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2019;126:611–622.
  48. Preiss D, et al. Effect of fenofibrate on progression of diabetic retinopathy (LENS). NEJM Evid. 2024;3:EVIDoa2400179.
  49. Nederlands Oogheelkundig Gezelschap. Richtlijn Diabetische retinopathie — module Timing cataractextractie bij retinopathie (Richtlijnendatabase, 2018).
  50. National Institute for Health and Care Excellence. Cataracts in adults: management (NG77). 2017.
  51. Zhang R, et al. EClinicalMedicine. 2022;49:101463 (Bayesian network meta-analysis, 17 randomized trials); Hsu C-A, et al. J Pers Med. 2022;12(3):351 (network meta-analysis).
  52. American Academy of Ophthalmology. Intravitreal Injection Policy Statement. Revised February 2025.
  53. Royal College of Ophthalmologists. Ophthalmic Service Guidance: Intravitreal Injection Therapy. 2018.
  54. Zhou Y, et al. Sustained elevation of intraocular pressure associated with intravitreal administration of anti-VEGF: a systematic review and meta-analysis. Sci Rep. 2016;6:39301.
  55. American Academy of Ophthalmology. Retinal Vein Occlusions PPP (2019); Age-Related Macular Degeneration PPP (2026).
  56. Fluorescein sodium injection: US prescribing information (Fluorescite, 2026) and UK Summary of Product Characteristics (2024). Iluvien: US prescribing information and UK Summary of Product Characteristics (2025).